02:54 PM EST - ProMIS Neurosciences, Inc. : Announced that its lead product candidate for Alzheimer's disease, PMN310, showed similar ability to cross the blood brain barrier and penetrate the central nervous system, compared to aducanumab. ProMIS Neurosciences, Inc.
shares T.PMN are trading up $0.10 at $0.47.
